VP, Head of Cell & Genetic Medicines Discovery

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

Interleukin-23 Inhibitors Market to Surge During the Forecast Period (2025-2034) Due to Demand for Targeted Autoimmune Therapies | DelveInsight

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi

Principal Scientist, Cell & Gene Therapy API

Johnson & Johnson is a leader in healthcare innovation focused on developing smarter and less invasive treatments. The Principal Scientist will join the Virology team to lead API development activities for Cell & Gene Therapy programs, ensuring viral safety and clearance while collaborating with various teams to drive scientific excellence.

Global Head of Protein Development

Scientist; RNA, Gene Therapy, & Delivery

Senior Scientist, Cell Therapy Platform and Discovery 

Principal Scientist Cell Pharm

Senior Scientist, Cell Therapy Platform, Therapeutics Discovery

Sign up with Google

Sign in with Google